Tatva Chintan Pharma Chem Ltd - 543321 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, please find enclosed Compliance Certificate for the quarter ended 31 March 2023, received from M/s Link Intime India Private Limited, our Registrar and Share Transfer Agent. The above information shall be uploaded on the website of the Company at www.tatvachintan.com. Tatva Chintan Pharma Chem Ltd - 543321 - Disclosure Under Regulation 30 Read With The Para B Of Part A Of Schedule III Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 Regarding Intimation Of Commencement Of Commercial Production Of New Facility At Dahej Manufacturing Plant
Pursuant to Regulation 30 read with Para B of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we are pleased to inform you that the Company has successfully commenced its commercial production from New Facility at our Dahej Manufacturing plant situated at Plot No.: Z/103/F/1&2, SEZ Area, Part-2, Dahej, Bharuch, Gujarat - 392130 on 05 April 2023. The above information shall be made available on the website of the Company at www.tatvachintan.com. Tatva Chintan Pharma Chem Ltd - 543321 - Closure of Trading Window
Pursuant to provisions of SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended and Company''s code on prohibition of insider trading, the 'Trading Window' for dealing in the securities of the Company shall remain closed for all Designated Persons and their immediate relatives from Saturday, 01 April 2023 till the completion of 48 hours after the Audited Financial Results of the Company for the quarter and financial year ending 31 March 2023 become Generally Available Information. Accordingly, all Designated Persons and their immediate relatives of the Company have been advised not to trade in the securities of the Company during the aforesaid period of Closure of Trading Window. Tatva Chintan Pharma Chem Ltd - 543321 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst / Institutional Investor Meeting under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Tatva Chintan Pharma Chem Ltd - 543321 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst / Institutional Investor Meeting under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Tatva Chintan Pharma Chem Ltd - 543321 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst / Institutional Investor Meeting under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Tatva Chintan Pharma Chem Ltd - 543321 - Announcement under Regulation 30 (LODR)-Monitoring Agency Report
Pursuant to Regulation 32(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed a copy of the Monitoring agency report of the Company for the quarter ended 31 December 2022, issued by ICICI Bank Limited, appointed to monitor the utilization of proceeds of an Initial Public Offering ('IPO') of the Company. The above information shall be made available on the website of the Company at www.tatvachintan.com. Tatva Chintan Pharma Chem Ltd - 543321 - Statement Of Deviation / Variation In Utilization Of Funds Raised Through IPO
Pursuant to Regulation 32(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed herewith statement of deviation(s) or variation(s) in utilization of funds raised through Initial Public Offering (IPO) for the quarter ended 31 December 2022 in the prescribed format. The same will be filed in XBRL mode separately. We confirm that, as at 31 December 2022, there has not been any deviation(s) or variation(s) in the utilization of net proceeds of IPO as mentioned in the objects stated in the Prospectus dated 22 July 2021. Report issued by Monitoring agency report is being separately filed with the exchange. The above information shall be made available on the website of the Company at www.tatvachintan.com. Tatva Chintan Pharma Chem Ltd - 543321 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed herewith the transcript of the earnings call held on 24 January 2023 post announcement of financial results of the Company for the quarter and nine months ended 31 December 2022. The above information shall be made available on Company's website of at www.tatvachintan.com. Tatva Chintan Pharma Chem Ltd - 543321 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to regulation 30 and 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we are enclosing herewith copies of newspaper publication of extract of financial results of the Company for the quarter and nine months ended 31 December 2022, published in Financial Express (English edition) and Vadodara Samachar (Gujarati edition) on 25 January 2023. The above information shall be made available on the website of the Company at www.tatvachintan.com.